SEC Filing Summary
Entity mismatch: The supplied filing is StemCells, Inc.’s Form 10-Q for the quarter ended June 30, 2012, not a Microbot Medical Inc. filing. The summary below describes StemCells, Inc.
Business context and reporting period
StemCells was a biopharmaceutical company developing stem-cell therapeutics and related research products. Its therapeutic programs included HuCNS-SC for Pelizaeus-Merzbacher disease, chronic spinal cord injury, and dry age-related macular degeneration. The unaudited report covers the three and six months ended June 30, 2012, with comparisons to 2011.
Financial performance and liquidity
| Metric | Three months ended June 30, 2012 | Six months ended June 30, 2012 |
|---|---|---|
| Revenue | $248,834 | $892,870 |
| Gross profit | $184,557 | $756,634 |
| Operating loss | $(5,349,753) | $(10,675,547) |
| Net income (loss) | $833,522 | $(9,395,917) |
| Net income (loss) per share | $0.03 | $(0.39) |
- Second-quarter gross margin was approximately 74%; six-month gross margin was approximately 85%, calculated as reported gross profit divided by total revenue.
- Second-quarter net income reflected a $6.2 million noncash gain from remeasuring warrant liabilities; the company remained loss-making from operations.
- For the first six months, operating cash use was $10.7 million, compared with $13.1 million in 2011. Investing activities provided $1.6 million, while financing provided $3.1 million, mainly from warrant exercises.
- At June 30, cash and cash equivalents were $7.2 million and current marketable securities were $1.7 million, totaling $8.9 million. Cash and cash equivalents had been $13.3 million at December 31, 2011.
- Current assets were $10.4 million and current liabilities $4.3 million. Total liabilities were $11.6 million; bonds payable were $430,000. Stockholders’ equity was $5.4 million.
- Contractual cash obligations totaled $19.2 million, principally operating leases ($18.7 million); this includes long-term rent commitments and should not be read as current debt.
Changes versus the prior comparable period
- Second-quarter revenue increased 6% year over year to $249,000; six-month revenue increased 96% to $893,000. Product sales rose 14% in the quarter and 44% in the half year. Six-month licensing and grant revenue increased 238%, primarily due to a genOway license agreement.
- Operating expenses fell 24% in both periods: to $5.5 million for the quarter and $11.4 million for six months. Lower research and development and administrative spending reflected workforce reductions, U.K. consolidation, relocation-related facility savings, and lower external services.
- The quarterly net result improved from a $4.0 million loss to $834,000 income, largely because the warrant-liability fair-value gain rose to $6.2 million. Six-month net loss narrowed modestly to $9.4 million from $9.8 million, while the warrant gain was lower than in 2011.
- Shares outstanding were 25.4 million at June 30, versus 22.4 million at December 31, 2011. The filing reports 30.4 million shares issued and outstanding at August 6, 2012, following subsequent warrant exercises and stock sales.
Outlook, risks, contingencies, and notable events
- Management expected additional operating losses and stated that substantial additional capital was required. The filing warns that if financing cannot be obtained after cash reserves are exhausted, the company could be unable to meet operating obligations and might have to initiate bankruptcy proceedings.
- In July 2012, the company sold 4,207,361 shares at an average $2.06 per share for approximately $8.7 million gross proceeds, before the sales agent’s 3% fee. Also after quarter-end, 691,000 Series A warrants were exercised for $967,400 gross proceeds.
- In July 2012, CIRM approved an award of up to $20 million over a maximum four-year period for preclinical development of HuCNS-SC for cervical spinal cord injury, targeting an IND filing. Funding to for-profit companies was to be structured as loans under terms and conditions to be agreed; it should not be treated as unconditional grant cash.
- Clinical updates included preliminary evidence of donor-cell myelination and functional gains in the small four-patient PMD study; the first interim safety review in the spinal cord injury trial reported treatment was well tolerated; and a Phase I/II dry AMD trial began in June 2012. These are early-stage findings, not proof of efficacy.
- Material risks include clinical and regulatory uncertainty, need for further capital and possible dilution, dependence on future partnerships or financing, patent validity and litigation, and ongoing Rhode Island facility costs. Neuralstem patent litigation remained in discovery, with trial anticipated in 2013.
- Nasdaq listing moved to the Capital Market effective July 16, 2012 after the company fell below the Global Market’s equity requirement. Nasdaq notified the company July 31 that it had regained compliance with the minimum bid-price requirement.
- The company reported effective disclosure controls and no material change in internal control over financial reporting during the quarter. It reported no material change to the risk factors in its 2011 Form 10-K.
Most important facts for investors to verify
- Confirm the issuer: the supplied filing is for StemCells, Inc., not Microbot Medical Inc.
- Assess near-term cash runway against the $10.7 million first-half operating cash burn, falling cash balance, and continuing development costs.
- Verify the terms, timing, and availability of the CIRM award, including its loan structure and conditions, and distinguish it from cash already received.
- Separate operating performance from warrant remeasurement gains when evaluating reported quarterly income; track potential dilution from outstanding warrants and subsequent share issuance.
- Review clinical trial progress, regulatory decisions, patent litigation, lease obligations, and continued Nasdaq listing compliance.